Therapeutic drug monitoring of antithyroid drugs in pregnancy: the knowledge gaps

Ther Drug Monit. 2006 Feb;28(1):12-3. doi: 10.1097/01.ftd.0000192135.54477.d9.

Abstract

Despite being a common condition in pregnancy, and despite propylthiouracil (PTU) being perceived as safer than methimazole, there are virtually no epidemiological controlled studies on malformation rate an neurobehavioral outcomes with the former. This knowledge gap must be filled to ensure fetal safety.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Abnormalities, Drug-Induced / etiology
  • Antithyroid Agents / adverse effects
  • Antithyroid Agents / blood*
  • Antithyroid Agents / pharmacokinetics
  • Drug Administration Schedule
  • Drug Monitoring
  • Female
  • Humans
  • Infant, Newborn
  • Knowledge
  • Maternal-Fetal Exchange
  • Methimazole / adverse effects
  • Methimazole / blood*
  • Methimazole / pharmacokinetics
  • Milk, Human / chemistry
  • Pregnancy
  • Propylthiouracil / adverse effects
  • Propylthiouracil / blood*
  • Propylthiouracil / pharmacokinetics
  • Thyrotoxicosis / chemically induced

Substances

  • Antithyroid Agents
  • Methimazole
  • Propylthiouracil